Phase 2 Completed N=41 Randomized Quadruple-blind Other

Ubiquinol (Reduced COQ10) for Patients With Sepsis

Sepsis

Source: ClinicalTrials.gov NCT01948063 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcomePrimary: CoQ10 Levels — 0.38; 0.87 (mcg/mL)

Summary

This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.

Outcome Measures

Outcome	Result	p-value
PRIMARY CoQ10 Levels	0.38; 0.87	—

Eligibility Criteria

Inclusion Criteria

Over 18 years old
Suspected or confirmed infection
Presence of 2 or more systemic inflammatory response syndrome (SIRS) criteria
Admission to the ICU

Exclusion Criteria

Under 18 years old
Current CoQ10 supplementation
Unable to receive enteral medications
Would need a nasogastric or orogastric tube solely for the purposes of the study
Pregnancy, incarceration, mentally disability
Patient confirmed Comfort measures only, Do not resuscitate (DNR) and/or Do not intubate. Patients with DNR but intubated and being provided full care are eligible

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01948063). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.